FTC Suspends Challenge to Block Amgen’s $27.8 Billion Deal to Purchase Horizon Therapeutics

The U.S. Federal Trade Commission (FTC) has suspended its challenge of Amgen’s $27.8 billion purchase of Horizon Therapeutics, allowing the FTC to consider whether the agency should settle the case, a filing late on Friday showed.

The pause is effective until Sept. 18.

Amgen said the company was aware of the move and is prepared to demonstrate that there is no legal or factual reason to prohibit the acquisition to the courts.

“We would be pleased if our commitment were honored instead of going through a lengthy court process,” the company said in a statement adding that it anticipates closing the acquisition by mid- December this year.

Read the source article at U.S. News